Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a New TCR-Based Cell Therapy Company and Holding Company TIO Bioventures | No more news
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a New TCR-Based Cell Therapy Company, and TIO Bioventures Portfolio Company
Category: More news
Posted on Saturday, October 16, 2021 12:05 PM
Combination Brings Additional Therapeutic Modality to Treadwell’s Growing Preclinical Pipeline of First-Class Agents and Proprietary Platforms
TCRyption’s initial programs could go into clinical practice in early 2023
NEW YORK, NY, USA & HONG KONG, China I October 15, 2021 I Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company specializing in novel approaches to TCR-based T cell therapy and a portfolio company of TIO Bioventures. The share exchange brings the unique and powerful technology of the TCRypt platform as well as a large number of TCR candidates with potential cancer utility into Treadwell’s growing and highly productive R&D organization. The platform can be used to identify TCRs recognizing a wide range of epitopes, regardless of haplotype, with unmatched sensitivity and speed. Scientists at Treadwell will take advantage of the technology to create a large library of TCRs recognizing a variety of epitopes. The bank’s first clinical studies of TCRs could begin in early 2023.
Currently available approaches to autologous TCR-based cell therapy focus on TCRs recognizing HLA-A2 restricted epitopes, alleles well represented in Caucasian populations. Although long-lasting remissions have been observed in HLA-A2-restricted TCR transgenic T cells, particularly those recognizing NY-ESO-1, the inclusion criteria for HLA-A2 may limit patient recruitment and business opportunities. Using a diverse set of proprietary tools, the TCRypt platform enables the identification of TCRs that are beyond the HLA-A2 restriction and recognize a diverse set of Class I and II alleles, including haplotypes widespread in Asian populations.
TCRyption, Inc. was originally formed with $ 10 million in seed funding from TIO Bioventures. The founders of TCRyption included visionary pioneers in T cell biology, such as Drs. Mark Davis and Tak Mak, who co-discovered the T cell receptor, Dr Naoto Hirano, who developed the TCRypt platform, and Dr Pamela Ohashi. The board of directors and shareholders of Treadwell and TCRyption have unanimously approved the combination.
“We are delighted to integrate this unique technology into Treadwell’s diverse portfolio of first-class drugs,” said Dr. Michael Tusche, Co-CEO of Treadwell Therapeutics. “We believe that the TCRypt platform will allow us to move beyond the narrow focus on HLA-A2 restricted epitopes and significantly expand the patient populations that can be treated with this approach. We hope to enter the clinic with several non-A2 restricted TCRs in different tumor types in early 2023. ”
“By combining Treadwell with TCRyption, we expect to achieve substantial operational efficiencies and better leverage our rapidly growing and talented global R&D organization,” added Dr Shane Burgess, President and Co-CEO of Treadwell.
About Treadwell Therapeutics
Treadwell Therapeutics is a science-based, clinical-stage, multimodal oncology company that develops world-class, best-in-class drugs to meet the unmet needs of cancer patients.
The Company’s robust and in-house pipeline includes a first-order PLK4 kinase inhibitor, CFI-400945 and a first-order TTK inhibitor, CFI-402257 and CFI-402411, an oral immunomodulatory kinase inhibitor with activity against HPK1 in Phase 1/2 studies. Treadwell also has a strong preclinical pipeline with several next-generation, biological TCR-based autologous cell therapy programs. For more information, please visit www.treadwelltx.com.
About TIO Bioventures
TIO Bioventures is a business start-up company specializing in financing the advancement of innovative healthcare companies guided by its principles of using rigorous science to create first-class cancer drugs that improve outcomes and performance. quality of life for patients with unmet needs.
THE SOURCE: Treadwell Therapeutics